Te Ahumairangi Investment Management Ltd Sells 2,050 Shares of Elevance Health, Inc. $ELV

Te Ahumairangi Investment Management Ltd decreased its holdings in Elevance Health, Inc. (NYSE:ELV) by 12.1% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 14,954 shares of the company’s stock after selling 2,050 shares during the quarter. Te Ahumairangi Investment Management Ltd’s holdings in Elevance Health were worth $5,242,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in shares of Elevance Health by 0.6% in the third quarter. Vanguard Group Inc. now owns 22,998,645 shares of the company’s stock valued at $7,431,322,000 after buying an additional 141,747 shares during the last quarter. Wellington Management Group LLP grew its holdings in Elevance Health by 4.8% during the 3rd quarter. Wellington Management Group LLP now owns 6,621,297 shares of the company’s stock worth $2,139,473,000 after acquiring an additional 303,099 shares during the last quarter. Artisan Partners Limited Partnership increased its position in Elevance Health by 24.5% in the 3rd quarter. Artisan Partners Limited Partnership now owns 4,576,805 shares of the company’s stock valued at $1,478,857,000 after acquiring an additional 901,626 shares in the last quarter. First Eagle Investment Management LLC increased its position in Elevance Health by 0.6% in the 4th quarter. First Eagle Investment Management LLC now owns 4,022,874 shares of the company’s stock valued at $1,410,219,000 after acquiring an additional 24,271 shares in the last quarter. Finally, Norges Bank bought a new position in shares of Elevance Health in the fourth quarter worth about $1,058,165,000. Institutional investors own 89.24% of the company’s stock.

Elevance Health Price Performance

ELV opened at $399.64 on Friday. The company has a fifty day moving average price of $364.53 and a two-hundred day moving average price of $344.44. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.48 and a current ratio of 1.48. Elevance Health, Inc. has a 52 week low of $273.71 and a 52 week high of $426.98. The firm has a market capitalization of $86.79 billion, a PE ratio of 17.00, a P/E/G ratio of 2.29 and a beta of 0.67.

Elevance Health (NYSE:ELV) last posted its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The company had revenue of $49.49 billion for the quarter, compared to the consensus estimate of $48.21 billion. During the same quarter in the prior year, the business posted $11.97 EPS. The firm’s quarterly revenue was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, analysts anticipate that Elevance Health, Inc. will post 26.93 earnings per share for the current year.

Elevance Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 25th. Shareholders of record on Wednesday, June 10th will be paid a $1.72 dividend. The ex-dividend date of this dividend is Wednesday, June 10th. This represents a $6.88 annualized dividend and a yield of 1.7%. Elevance Health’s dividend payout ratio is presently 29.26%.

Analyst Ratings Changes

Several analysts have recently commented on ELV shares. JPMorgan Chase & Co. increased their price target on shares of Elevance Health from $411.00 to $476.00 and gave the company an “overweight” rating in a research note on Monday. UBS Group boosted their price objective on shares of Elevance Health from $400.00 to $460.00 and gave the stock a “buy” rating in a research report on Friday, May 22nd. Bank of America upped their price objective on Elevance Health from $435.00 to $460.00 and gave the stock a “buy” rating in a report on Thursday, June 4th. Leerink Partners set a $364.00 target price on Elevance Health in a research note on Thursday, April 23rd. Finally, Barclays boosted their target price on Elevance Health from $408.00 to $480.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 26th. Fourteen equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, Elevance Health currently has an average rating of “Moderate Buy” and a consensus price target of $416.11.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.